应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台 » 生物医药区 » 新药研发 » 质量控制 » 【求助】氯雷他定片 国外标准
31/1返回列表
查看: 457  |  回复: 2
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看

2010020170

金虫 (小有名气)

[交流] 【求助】氯雷他定片 国外标准 已有2人参与

有谁知道 氯雷他定片的国外标准 我不知道在哪可以查到 谢谢
回复此楼

» 猜你喜欢

» 本主题相关价值贴推荐，对您同样有帮助:
让自己活得精彩
1楼 2011-01-11 18:22:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

主救

金虫 (正式写手)

海阔天空
★ ★ ★
小木虫(金币+0.5):给个红包，谢谢回帖交流
koria0727(金币+2):谢谢提供。 2011-01-15 16:36:11
USP32-NF27收载过。
Loratadine Tablets
» Loratadine Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of loratadine (C22H23ClN2O2).
Packaging and storage— Preserve in tight containers, and store between 2 and 30. Protect from excessive moisture if packaged in blisters.
USP Reference standards 11—
USP Loratadine RS  .
Identification—
A: Thin-Layer Chromatographic Identification Test 201—
Test solution— Transfer an accurately weighed quantity of Tablets, equivalent to about 20 mg of loratadine, to a centrifuge tube. Add 5.0 mL of a mixture of chloroform and methanol (1:1), rotate for 30 minutes, and centrifuge.
Standard solution— Dissolve an accurately weighed quantity of about 20 mg of USP Loratadine RS in 5 mL of a mixture of chloroform and methanol (1:1), and mix.
Application volume: 5 µL.
Developing solvent system: ethyl ether and diethylamine (40:1), in a paper-lined tank.
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Dissolution 711—
Medium: 0.1 N hydrochloric acid; 900 mL.
Apparatus 2: 50 rpm.
Time: 60 minutes.
Procedure— Determine the amount of C22H23ClN2O2 dissolved from UV absorption at the wavelength of maximum absorbance at about 280 nm on filtered portions of the solution under test, suitably diluted with Dissolution Medium, if necessary, in comparison with a Standard solution having a known concentration of USP Loratadine RS in the same Medium.
Tolerances— Not less than 80% (Q) of the labeled amount of C22H23ClN2O2 is dissolved in 60 minutes.
Uniformity of dosage units 905: meet the requirements.
Related compounds—
0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, and Diluent— Proceed as directed in the Assay under Loratadine.
Standard stock solution— Prepare as directed for Standard preparation in the Assay under Loratadine.
Standard solution— Pipet 5.0 mL of the Standard stock solution into a 100-mL volumetric flask, and dilute with Diluent to volume. Dilute quantitatively, and stepwise if necessary, with Diluent to obtain a solution having a known concentration of about 0.8 µg per mL.
Test solution— Use the Assay preparation.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L7. The flow rate is about 1 mL per minute. Chromatograph the Test solution, and record the peak areas as directed for Procedure: the relative retention times are about 0.79 for 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl and 1.0 for loratadine. Chromatograph the Standard solution, and record the peak areas of the main peak as directed for Procedure: the relative standard deviation for replicate injections is not more than 4.0%.
Procedure— Separately inject equal volumes (about 50 µL) of the Test solution and the Standard solution into the chromatograph, record the chromatograms, and measure all of the peak area responses in the Test solution and the peak area of the main peak in the Standard solution. Calculate the percentage of each impurity in the portion of Tablets taken by the formula:
2500(C/L)(ri / rS)
in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard solution; L is the labeled quantity, in mg, of loratadine in each Tablet taken; ri is the peak area response for each impurity in the Test solution; and rS is the peak area response of loratadine in the Standard solution: not more than 0.2% of 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl is found; not more than 0.1% of any other individual impurity is found; and the sum of all impurities, other than 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl, is not more than 0.1%.
Assay—
0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, Diluent, and Standard preparation— Proceed as directed in the Assay under Loratadine.
Assay preparation— Transfer 10 Tablets into a 250-mL volumetric flask, add 100 mL of 0.05 N Hydrochloric acid, and shake for 40 minutes or until the Tablets are completely disintegrated. Add 75 mL of a mixture of methanol and acetonitrile (1:1), and mix. Add 20 mL of 0.6 M Dibasic potassium phosphate, and mix for 5 minutes. Dilute with a mixture of methanol and acetonitrile (1:1) to volume, and mix.
Chromatographic system (see Chromatography 621)— Prepare as directed in the Assay under Loratadine. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k¢, is not less than 3.5; the tailing factor is not more than 1.7; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 15 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak response for the major peaks. Calculate the quantity, in mg, of loratadine (C22H23ClN2O2) in the portion of Tablets taken by the formula:
250C(rU / rS)
in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Daniel K. Bempong, Ph.D.
Senior Scientist
1-301-816-8143 (MDPS05) Monograph Development-Pulmonary and Steroids
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org  
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
1-301-816-8106 (BPC05) Biopharmaceutics05

USP32–NF27 Page 2808
Pharmacopeial Forum: Volume No. 29(4) Page 1045
Chromatographic Column—
LORATADINE TABLETS
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.
赞一下(2人) 回复此楼
海阔天空
2楼2011-01-15 16:16:03
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

2010020170

金虫 (小有名气)
非常感谢
回复此楼
让自己活得精彩
3楼2011-01-16 13:04:49
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 2010020170 的主题更新
31/1返回列表
普通表情 龙 兔 虎 猫 高级回复 (可上传附件)
信息提示
关闭
请填处理意见
关闭